Literature DB >> 6201685

5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.

R L Momparler, J Bouchard, N Onetto, G E Rivard.   

Abstract

The effect of 5-aza-2'-deoxycytidine (5-AZA-dCyd) on methylation of DNA in blood leukemic cells from patients with lymphoid and myeloid leukemia was investigated. After treatment with continuous infusion of 5-AZA-dCyd (1.0 mg/kg/h) the blood leukemic cells were isolated and incubated in vitro with [6-3H]deoxycytidine and the incorporation of radioactivity into 5-methylcytosine and cytosine of DNA determined. 5-AZA-dCyd produced greater than 70% inhibition of DNA methylation in the leukemic cells. The antileukemic action of 5-AZA-dCyd may be related to the inhibition of DNA methylation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201685     DOI: 10.1016/0145-2126(84)90141-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.

Authors:  Ju Hwan Cho; Filiz Oezkan; Michael Koenig; Gregory A Otterson; James Gordon Herman; Kai He
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

Review 2.  Therapy with azanucleosides for myelodysplastic syndromes.

Authors:  Alfonso Quintás-Cardama; Fabio P S Santos; Guillermo Garcia-Manero
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 3.  DNA methylation as a target for drug design.

Authors:  C M Bender; J M Zingg; P A Jones
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

4.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

Review 5.  Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.

Authors:  Elias Jabbour; Jean-Pierre Issa; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 6.  MYC-Master Regulator of the Cancer Epigenome and Transcriptome.

Authors:  Candace J Poole; Jan van Riggelen
Journal:  Genes (Basel)       Date:  2017-05-13       Impact factor: 4.096

7.  Decitabine: a historical review of the development of an epigenetic drug.

Authors:  Dick de Vos; Wendy van Overveld
Journal:  Ann Hematol       Date:  2005-12       Impact factor: 3.673

Review 8.  Advances in epigenetic therapeutics with focus on solid tumors.

Authors:  Ning Jin; Tiffany L George; Gregory A Otterson; Claire Verschraegen; Haitao Wen; David Carbone; James Herman; Erin M Bertino; Kai He
Journal:  Clin Epigenetics       Date:  2021-04-20       Impact factor: 6.551

Review 9.  Demethylating Agents in the Treatment of Cancer.

Authors:  Paul M Howell; Zixing Liu; Hung T Khong
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.